These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Natesan M; Jensen SM; Keasey SL; Kamata T; Kuehne AI; Stonier SW; Lutwama JJ; Lobel L; Dye JM; Ulrich RG Clin Vaccine Immunol; 2016 Aug; 23(8):717-24. PubMed ID: 27335383 [TBL] [Abstract][Full Text] [Related]
30. Determination of specific antibody responses to the six species of ebola and Marburg viruses by multiplexed protein microarrays. Kamata T; Natesan M; Warfield K; Aman MJ; Ulrich RG Clin Vaccine Immunol; 2014 Dec; 21(12):1605-12. PubMed ID: 25230936 [TBL] [Abstract][Full Text] [Related]
31. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. Suschak JJ; Schmaljohn CS Hum Vaccin Immunother; 2019; 15(10):2359-2377. PubMed ID: 31589088 [TBL] [Abstract][Full Text] [Related]
32. Innate Immune Responses of Bat and Human Cells to Filoviruses: Commonalities and Distinctions. Kuzmin IV; Schwarz TM; Ilinykh PA; Jordan I; Ksiazek TG; Sachidanandam R; Basler CF; Bukreyev A J Virol; 2017 Apr; 91(8):. PubMed ID: 28122983 [TBL] [Abstract][Full Text] [Related]
33. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins. Nyakatura EK; Zak SE; Wec AZ; Hofmann D; Shulenin S; Bakken RR; Aman MJ; Chandran K; Dye JM; Lai JR J Biol Chem; 2018 Apr; 293(16):6201-6211. PubMed ID: 29500195 [TBL] [Abstract][Full Text] [Related]